Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M74.5Revenue (TTM) $M17.8Net Margin (%)420Altman Z-Score-8.5
Enterprise Value $M63.7EPS (TTM) $0.5Operating Margin %-15.7Piotroski F-Score7
P/E(ttm)1.0Beneish M-Score2.3Pre-tax Margin (%)-83.8Higher ROA y-yY
Price/Book3.410-y EBITDA Growth Rate %--Quick Ratio2.2Cash flow > EarningsN
Price/Sales4.05-y EBITDA Growth Rate %-42.2Current Ratio2.2Lower Leverage y-yY
Price/Free Cash Flow1.1y-y EBITDA Growth Rate %--ROA % (ttm)483Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M162ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with NAVB

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

NAVB is held by these investors:



NAVB: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Latkin JedCOO and CFO 2017-05-22Buy25,359$0.452.22view
LARSON BRENT LEVP, CFO, Treas & Sec'y 2015-12-01Sell12,500$1.5-69.33view
LARSON BRENT LEVP, CFO, Treas & Sec'y 2015-11-02Sell12,500$1.98-76.77view
LARSON BRENT LEVP, CFO, Treas & Sec'y 2015-10-01Sell12,500$2.27-79.74view
LARSON BRENT LEVP, CFO, Treas and Sec'y 2015-09-01Sell12,500$1.88-75.53view
LARSON BRENT LEVP, CFO, Treas and Sec'y 2015-08-03Sell12,500$1.71-73.1view
LARSON BRENT LEVP, CFO, Treas and Sec'y 2015-06-01Sell12,500$1.24-62.9view
Troup Gordon ADirector 2015-05-29Buy10,000$1.31-64.89view
FORD BRENDAN ADirector 2015-05-21Buy20,000$1.31-64.89view
LARSON BRENT LEVP, CFO, Treas and Sec'y 2015-05-01Sell12,500$1.33-65.41view

Quarterly/Annual Reports about NAVB:

News about NAVB:

Articles On GuruFocus.com
Navidea Biopharmaceuticals Reports 4 Insider Trades Mar 18 2013 

More From Other Websites
Edited Transcript of NAVB earnings conference call or presentation 10-May-17 12:00pm GMT May 18 2017
Navidea pays former CEO $618,000 after losing arbitration over his firing May 18 2017
Navidea posts 1Q profit May 09 2017
Navidea Biopharmaceuticals Reports First Quarter 2017 Financial Results May 09 2017
Navidea Biopharmaceuticals Invited to Present Data at Two Major Upcoming Conferences Apr 25 2017
ETFs with exposure to Navidea Biopharmaceuticals, Inc. : April 19, 2017 Apr 19 2017
Navidea Biopharmaceuticals, Inc. :NAVB-US: Earnings Analysis: Q4, 2016 By the Numbers : April 4,... Apr 04 2017
Navidea halved losses in 2016, projects positive cash flow in 2017 Mar 30 2017
Navidea reports 4Q loss Mar 29 2017
Navidea Provides Corporate Update and Reports Full Year 2016 Results Mar 29 2017
Why Navidea can recover no more than $12M if it wins against ex-lender in court Mar 13 2017
Navidea closes Lymphoseek sale to Cardinal Health; lender CRG accepts loan payment, drops liens Mar 06 2017
Navidea Completes Sale of North American Rights of Lymphoseek® to Cardinal Health Mar 03 2017
Cardinal Health helps Navidea settle lender's payoff – for now Feb 24 2017
Navidea to Hold Conference Call to Provide Investor Update on Status of Ongoing Corporate Events Jan 27 2017
Navidea to Present at Upcoming Investor Conference Jan 06 2017
ETFs with exposure to Navidea Biopharmaceuticals, Inc. : December 29, 2016 Dec 29 2016
Edited Transcript of NAVB earnings conference call or presentation 3-Nov-16 12:30pm GMT Nov 28 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat